Ioflubenzamide

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2009 (NCT00747825)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • MelaninBINDING AGENT

    Melanin binding agent

  • Unspecified targetRadiodepletion

    radiodepletion

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)CCNC(=O)c1cc(I)c(NC(=O)c2ccc(F)cc2)cc1OC
Mol. weight
513.35 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Payload
131-iodine

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 131i-mip-1145

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00747825Phase 1Dec 1, 2009Molecular Insight Pharmaceuticals
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Molecular Insight PharmaceuticalsFor profit1112009
1 organizations
Page 1 / 1